At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 125 enrolled
Drug / intervention
CG100649 +1 moredrug
Likely dose
Celecoxib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Multicenter, Noninferiority, Phase II Repeat Dose Study of CG100649 Versus Celecoxib in Osteoarthritis Patients
In Brief
A Phase 2 clinical trial evaluating CG100649 and Celecoxib for Osteoarthritis. Completed, enrolled 125 participants across 1 site.
Detailed Summary
This is a double-blind, randomized, multicenter, phase 2b, noninferiority comparison of two active dose levels of CG100649 vs. a standard anti-arthritic dose of celecoxib (Celebrex).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesSouth Korea
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedApr 2011
Primary CompletionDec 2011
Study CompletionJan 2012
TodayJul 2026
First PostedApr 25, 2011
Enrollment StartApr 1, 2011
Primary CompletionDec 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.2 years ago
Interventions
CG100649drug
once daily for 28 days
Celecoxibdrug
capsule, celecoxib 200 mg, once daily for 28 days